MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.710
+0.110
+6.88%
After Hours: 1.691 -0.019 -1.13% 19:49 05/13 EDT
OPEN
1.590
PREV CLOSE
1.600
HIGH
1.750
LOW
1.570
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
2.700
52 WEEK LOW
1.175
MARKET CAP
455.11M
P/E (TTM)
-1.5827
1D
5D
1M
3M
1Y
5Y
1D
Autolus Therapeutics Q1 2026 Earnings Preview
Seeking Alpha · 10h ago
Weekly Report: what happened at AUTL last week (0504-0508)?
Weekly Report · 2d ago
Weekly Report: what happened at AUTL last week (0427-0501)?
Weekly Report · 05/04 09:46
Analyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts
TipRanks · 04/30 10:27
Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
TipRanks · 04/29 22:57
Autolus Therapeutics to reduce workforce by approximately 13%
TipRanks · 04/29 22:04
Autolus Therapeutics Plans To Cut Workforce By ~13% As Part Of Initiative To Enhance Operational Efficiency, Lower Operating Expenses
Benzinga · 04/29 20:24
Autolus to cut about 13% of workforce in cost reduction initiative
Seeking Alpha · 04/29 20:20
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.